A transdermal patch is a galenic form containing a source of active substance that is released slowly while attached to the skin. Its aim is for the pharmaceutical to enter the systemic circulation through the skin surface and not the pharmaceutical’s activity in the skin itself.
As we keep getting older and older, steadily we include more pharmaceuticals in our every daylives, and for this motive, the patches that attach to the skin obtain a fundamental importance to avoid problems because of a great consumption of drugs, especially in the old age, and as well for your comfort.
Drug-device combination inventions, such as transdermal patch, established a new activity on medical product development, regulatory ratification, and corporate interaction that give us valuable lessons for the development of new types of combination solutions. Analysis indicate that the biggest obstacle to introduce a new type of combination products is the settlement of the regulatory center that would be to oversee its authorization, and so the device contract. The first invention of a new class of combination product gives a learning chance for the supervisor and the sponsor. Once that the first invention is approved, the leading regulatory center is determined, and the uncertainty about the whole kind of combination solutions is drastically reduced.
The promoter inventing a new kind of combination products undertakes a principal role in reducing this uncertainty by encouraging the decision on the main objective of the combination product. This decision influences the nature of the enterprises that will guide the implementation of these inventions into the market.